Your browser doesn't support javascript.
loading
Evaluation of ABO blood group in subjects with CVD risk factors in a population sample from northeastern Iran.
Yaghooti-Khorasani, Mahdiyeh; Ghazizadeh, Hamideh; Bijari, Moniba; Mohammadi-Bajgiran, Maryam; Oladi, Mohammad Reza; Zare-Feizabadi, Reza; Timar, Ameneh; Nazarpour, Shahin; Khedmatgozar, Hamed; Rohban, Mohadeseh; Hasanzadeh, Elahe; Javandoost, Ali; Banpoor, Hamed; Sheikh Andalibi, Mohammad Sobhan; Moazedi, Sara; Mosalman-Zadeh, Negin; Aghasizadeh, Maliheh; Ferns, Gordon A; Esmaily, Habibollah; Ghayour-Mobarhan, Majid.
Afiliação
  • Yaghooti-Khorasani M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Ghazizadeh H; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Bijari M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mohammadi-Bajgiran M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Oladi MR; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Zare-Feizabadi R; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Timar A; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nazarpour S; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Khedmatgozar H; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Center for Biotechnology and Genomics, Texas Tech University, Lubbock, TX, USA.
  • Rohban M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Hasanzadeh E; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
  • Javandoost A; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Banpoor H; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Sheikh Andalibi MS; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Moazedi S; Department of Nutrition Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.
  • Mosalman-Zadeh N; Department of Nutrition Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.
  • Aghasizadeh M; Student Research Committee, Department of Molecular Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
  • Ferns GA; Division of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, Sussex, UK.
  • Esmaily H; Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: esmailyh@mums.ac.ir.
  • Ghayour-Mobarhan M; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Nutrition, Faculty of Medicine, Mashhad University of Med
Diabetes Metab Syndr ; 14(6): 1689-1695, 2020.
Article em En | MEDLINE | ID: mdl-32905941
ABSTRACT
BACKGROUND AND

AIMS:

The ABO blood group system is a genetic polymorphism which can affect the clearance of von Willebrand factor. We aimed to assess the levels of newer biomarkers of cardiovascular disease (CVD) risk; pro-oxidant-antioxidant balance (PAB), high sensitivity C-reactive protein (hs-CRP) and anti-heat-shock protein27 (anti-Hsp27) antibody titers in subjects with various blood groups (A, B, AB and O) and with or without traditional CVD risk factors.

METHODS:

The cross-sectional study comprised 6910 subjects. Antigen-antibody agglutination was evaluated by the slide test method for identification of ABO blood groups.

RESULTS:

Among three markers, only Serum anti-Hsp27 titers significantly differed between the four blood groups and showed the highest and lowest values in AB and O blood groups (0.26 ± 0.22 and 0.23 ± 0.18 OD, respectively; P < 0.05). Serum anti-Hsp27 was higher in individuals with an AB blood group with metabolic syndrome (MetS), dyslipidemia, hypertension (HTN) and obesity and it was lower in subjects with O blood group; though, two other biomarkers, serum PAB and hs-CRP, were not significantly different between the ABO blood groups. However, they were not different among blood groups in participants with or without diabetes mellitus (DM) (P > 0.05).

CONCLUSION:

Individuals with an AB blood group and high levels of anti-Hsp27 antibody titers may be predisposed to CVDs that can be mediated through the traditional CVD risk factors among middle-aged subjects from northeastern Iran. The fact that differences in anti Hsp27 are only found in the subgroup with other risk factors suggest that the difference between ABO blood groups is a consequence rather than a cause.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema ABO de Grupos Sanguíneos / Biomarcadores / Doenças Cardiovasculares / Oxidantes / Espécies Reativas de Oxigênio Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema ABO de Grupos Sanguíneos / Biomarcadores / Doenças Cardiovasculares / Oxidantes / Espécies Reativas de Oxigênio Idioma: En Ano de publicação: 2020 Tipo de documento: Article